FCGRs Polymorphisms and Response to Trastuzumab in Patients With HER2-Positive Breast Cancer: Far From Predictive Value?

BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were...

Descripción completa

Detalles Bibliográficos
Autores principales: Botticelli, Andrea, Mazzuca, Federica, Borro, Marina, Mazzotti, Eva, La Torre, Marco, Bonifacino, Adriana, Ciabatta, Francesca Romana, Gentile, Giovanna, Maddalena, Chiara, Simmaco, Maurizio, Marchetti, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5624668/
https://www.ncbi.nlm.nih.gov/pubmed/28983344
http://dx.doi.org/10.14740/wjon934w
Descripción
Sumario:BACKGROUND: The aim of the study was to validate the association between the Arg166His polymorphisms of the Fc immunoglobulin receptor 2A (FCGR2A) and the Val212Phe of FCGR3A and pathological clinical response (pCR) to trastuzumab in HER2-positive breast cancer patients. METHODS: Polymorphisms were characterized by pyrosequencing in 26 patients with ductal histotype breast cancer in a neoadjuvant setting and genotype association with pCR was analyzed. RESULTS: No association was found between the FCGR3A Val212Phe polymorphisms and pCR. In contrast, the FCGR2A GG genotype (Arg allele) was found to be positively associated with pCR (P = 0.012). CONCLUSIONS: Our results do not support previously reported data on the effect of polymorphisms in immunoglobulin Fc receptors upon response to trastuzumab therapy.

Ejemplares similares